Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Mehlika Toy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis D, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDC HHS, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
Chronic hepatitis D virus (HDV) infection increases the risk of liver-related deaths in adults with chronic hepatitis B (CHB). In the United States (US), only an estimated 12.9% of adults with CHB have received an HDV antibody test. The aim of this study is to calculate the cost-effectiveness of one-time universal HDV testing of hepatitis B surface antigen (HBsAg)–positive adults living in the US.
Methods
A Markov model was used to calculate the costs, health impact, and cost-effectiveness of universal testing of HBsAg-positive adults with an HDV antibody test and, when positive, an HDV RNA test for chronic HDV infection. We assumed that 50% of the HDV RNA–positive patients would receive the current recommended treatment with pegylated interferon (PEG-IFN) for 48 weeks with a 30% response rate. We also modeled the potential impact of hypothetical indefinite HDV antiviral therapy with a higher response rate to assess the annual cost threshold to be considered cost-effective.
Results
Universal HDV testing of adults with CHB could avert 100 HDV-related deaths and an additional 30 cases of cirrhosis and 50 cases of hepatocellular carcinoma, and potentially result in a gain of 1500 quality-adjusted life-years (QALYs) per 100 000 HBsAg-positive individuals screened. At a willingness-to-pay threshold of $50 000 per QALY, the annual drug costs for a hypothetical indefinite therapy with a 50% or 70% treatment response rate would need to cost ≤$13 027 and ≤$14 104, respectively.
Conclusions
One-time HDV testing for all HBsAg-positive adults and treatment of chronic HDV infection with PEG-IFN is potentially cost-effective in the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
- Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
- Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, California, USA.
- Department of Health Policy, Stanford University School of Medicine, Stanford, California, USA.
- Center for Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, California, USA.
ORCID-Profile: David Hutton, William W Thompson, Joshua A Salomon
Förderung
- CDC HHS
- National Center for HIV, Viral Hepatitis, STD, and TB Prevention
- Centers for Disease Control and Prevention
Zitieren
APA
Toy, M., Hutton, D., Teshale, E., Thompson, W. W., Pham, H., Salomon, J. A., & So, S. (2025). Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf181
Vancouver
Toy M, Hutton D, Teshale E, Thompson WW, Pham H, Salomon JA, et al. Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf181
BibTeX
@article{Toy2025,
author = {Toy, Mehlika and Hutton, David and Teshale, Eyasu and Thompson, William W and Pham, Hang and Salomon, Joshua A and So, Samuel},
title = {Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf181}
}
EUVIMED